Formycon AG (FRA:FYB)

Market Cap	428.36M
Revenue (ttm)	48.07M
Net Income (ttm)	-165.17M
Shares Out	n/a
EPS (ttm)	-9.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,759
Average Volume	675
Open	24.45
Previous Close	24.25
Day's Range	23.10 - 24.45
52-Week Range	18.62 - 63.70
Beta	n/a
RSI	52.32
Earnings Date	Nov 13, 2025

About Formycon AG

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 250
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: FYB